Literature DB >> 33348039

The use of atropine for treatment of amblyopia using the OptumLabs Data Warehouse.

Stacy L Pineles1, Michael X Repka2, Fei Yu3, Federico G Velez4, Claudia Perez5, Danielle Sim5, Anne L Coleman6.   

Abstract

Atropine and patching are standard treatments for amblyopia, but the prevalence of atropine therapy in the United States is unknown. This study used the OptumLabs Data Warehouse to evaluate pharmacy claims for topical atropine to evaluate the frequency of its treatment for amblyopia and to compare demographic factors in cohorts of amblyopic children who were and were not prescribed atropine. Overall, 55.2% of amblyopic children were prescribed atropine more than once. The children who were prescribed atropine had a higher likelihood of living in geographic regions in the South or Midwest.
Copyright © 2020 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33348039      PMCID: PMC9037612          DOI: 10.1016/j.jaapos.2020.11.003

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  9 in total

1.  Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children.

Authors:  Michael X Repka; David K Wallace; Roy W Beck; Raymond T Kraker; Eileen E Birch; Susan A Cotter; Sean Donahue; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Mitchell M Scheiman; David R Weakley
Journal:  Arch Ophthalmol       Date:  2005-02

2.  What to do about racial disparities in access to glasses among children in the US?

Authors:  Nathan Congdon
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-10-30       Impact factor: 4.799

3.  A randomized trial of atropine regimens for treatment of moderate amblyopia in children.

Authors:  Michael X Repka; Susan A Cotter; Roy W Beck; Raymond T Kraker; Eileen E Birch; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Nicholas A Sala; Mitchell M Scheiman; David R Stager; David K Wallace
Journal:  Ophthalmology       Date:  2004-11       Impact factor: 12.079

4.  A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children.

Authors: 
Journal:  Arch Ophthalmol       Date:  2002-03

5.  The clinical profile of moderate amblyopia in children younger than 7 years.

Authors: 
Journal:  Arch Ophthalmol       Date:  2002-03

6.  Prevalence of amblyopia and strabismus in African American and Hispanic children ages 6 to 72 months the multi-ethnic pediatric eye disease study.

Authors: 
Journal:  Ophthalmology       Date:  2007-10-22       Impact factor: 12.079

7.  Prevalence of amblyopia and strabismus in white and African American children aged 6 through 71 months the Baltimore Pediatric Eye Disease Study.

Authors:  David S Friedman; Michael X Repka; Joanne Katz; Lydia Giordano; Josephine Ibironke; Patricia Hawse; James M Tielsch
Journal:  Ophthalmology       Date:  2009-09-16       Impact factor: 12.079

8.  Sight-Threatening Ocular Diseases Remain Underdiagnosed Among Children Of Less Affluent Families.

Authors:  Joshua D Stein; Chris Andrews; David C Musch; Carmen Green; Paul P Lee
Journal:  Health Aff (Millwood)       Date:  2016-08-01       Impact factor: 6.301

9.  Treatment of severe amblyopia with weekend atropine: results from 2 randomized clinical trials.

Authors:  Michael X Repka; Raymond T Kraker; Roy W Beck; Eileen Birch; Susan A Cotter; Jonathan M Holmes; Richard W Hertle; Darren L Hoover; Deborah L Klimek; Wendy Marsh-Tootle; Mitchell M Scheiman; Donny W Suh; David R Weakley
Journal:  J AAPOS       Date:  2009-06       Impact factor: 1.220

  9 in total
  1 in total

1.  Effect of 0.01% Atropine on Accommodation in Myopic Teenagers.

Authors:  Huixia Li; Liying Zhang; Hong Tian; Song Zhang; Xueyan Zhang; Han Zhang; Yujing Chen; Wenping Qi; Xiaoying Wu; Hongmei Jiang; Hailong Yang; Yajun Yang; Lei Liu; Guisen Zhang
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.